Skip to main content
. 2019 May 14;39(5):BSR20190350. doi: 10.1042/BSR20190350

Figure 4. Effect of TGF-β1 on degradation and ubiquitination of Runx2 in denervated cancellous bone.

Figure 4

(A) Western blotting of Runx2 protein from denervated-cancellous bone of Sham + Veh and DNV + Veh groups. (B) Quantitative determination of Runx2 protein in (A). (C) The immunoprecipitated of HA-Runx2 protein in Sham + Veh and DNV + Veh groups. (D) Quantitative determination of the polyubiquitinated Runx2 abundance in (C). (E) Blockade of Runx2 protein degradation by the proteasome inhibitors. (F) Western blotting of Runx2 protein in denervated-cancellous bone from Sham + Veh, Sham + TGF, DNV + Veh, and DNV + TGF groups at 3 weeks. (G) The immunoprecipitated of exogenous Runx2 in the denervated-cancellous bone from Sham + Veh, Sham + TGF, DNV + Veh, and DNV + TGF groups at 3 weeks. (H) Quantitative determination of the poly-ubiquitinated Runx2 abundance shown in (G). (I) Total body weight in four groups. *P<0.05. For all time points per group, n=7.